14M172: Closing Session: ACR Convergence 2022 Wrap-up

Monday, November 14, 2022

6:00 PM – 7:00 PM Eastern Time

Location: Ballroom AB

CE: 1

All of the relevant financial relationships listed for faculty have been mitigated.

Panelist(s)

Daniel White, PT, ScD

University of Delaware
Newark, DE, United States

Disclosure(s): No financial relationships to disclose

Moderator(s)

Peter Merkel, MD, MPH

University of Pennsylvania
Philadelphia, PA, United States

Disclosure(s): AbbVie: Consultant (Ongoing), Grant/Research Support (Ongoing); AstraZeneca: Consultant (Ongoing), Grant/Research Support (Ongoing); Boeringher-Ingelheim: Consultant (Ongoing), Grant/Research Support (Ongoing); Bristol-Myers Squibb: Consultant (Ongoing), Grant/Research Support (Ongoing); ChemoCentryx: Consultant (Ongoing), Grant/Research Support (Ongoing); CSL Behring: Consultant (Ongoing); Dynacure: Consultant (Ongoing); Eicos: Grant/Research Support (Ongoing); Electra: Grant/Research Support (Ongoing); EMDSerono: Consultant (Terminated, December 31, 2021); Forbius: Consultant (Terminated, December 31, 2021), Grant/Research Support (Terminated, December 31, 2021); Genentech/Roche: Consultant (Terminated, December 31, 2021), Grant/Research Support (Terminated, December 31, 2021); Genzyme/Sanofi: Consultant (Terminated, December 31, 2021), Grant/Research Support (Terminated, December 31, 2021); GlaxoSmithKline: Consultant (Ongoing), Grant/Research Support (Ongoing); Immagene: Consultant (Ongoing); InflaRx: Consultant (Ongoing), Grant/Research Support (Ongoing); Jannsen: Consultant (Ongoing); Kiniksa: Consultant (Terminated, July 31, 2020); Kyverna: Consultant (Ongoing), Stock options or bond holdings in a for-profit corporation or self-directed pension plan (Ongoing); Magenta: Consultant (Ongoing); Neutrolis: Consultant (Ongoing), Grant/Research Support (Ongoing); Novartis: Consultant (Ongoing); Pfizer: Consultant (Ongoing); Q32: Consultant (Ongoing); Regeneron: Consultant (Ongoing); Sparrow: Consultant (Ongoing); Takeda: Consultant (Ongoing), Grant/Research Support (Ongoing); UpToDate: Royalties (Ongoing)

Panelist(s)

Alfred Kim, MD, PhD

Washington University School of Medicine
St. Louis, MO, United States

Disclosure(s): Alexion Pharmaceuticals: Consultant (Ongoing); AstraZeneca: Consultant (Ongoing); Aurinia Pharmaceuticals: Consultant (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Exagen Diagnostics: Consultant (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Foghorn Therapeutics: Grant/Research Support (Ongoing); GlaxoSmithKline: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Kypha Inc.: Consultant (Ongoing), Intellectual Property/Patents (Ongoing); Pfizer: Consultant (Ongoing)
Kristi Kuhn, MD, PhD

2022 - 2023 / Adult/ University of Colorado
Aurora, CO, United States

Disclosure(s): Pfizer: Grant/Research Support (Ongoing); UCB: Consultant (Ongoing)

Join us for this inspiring closing session highlighting memorable moments from ACR Convergence 2022. This roundtable discussion will feature key learning takeaways, highlights from community hosts and actionable insights delivered by an engaging and diverse panel of experts. Look to the future of rheumatology and what’s ahead for 2023.

Learning Objectives:

Summarize recent developments in the diagnosis and management of patients with rheumatic diseases.
Describe potential challenges in the delivery of care to patients with rheumatic diseases and specify possible solutions
Summarize recent rheumatology research findings.

Presentations:

6:00 PM – 6:05 PM Eastern Time

Welcome and Introductions
Speaker: Peter Merkel, MD, MPH – University of Pennsylvania
6:55 PM – 7:00 PM Eastern Time

Closing Remarks
Speaker: Peter Merkel, MD, MPH – University of Pennsylvania